New chemo combo aims to stop leukemia return after transplant
NCT ID NCT01885689
First seen Nov 16, 2025 · Last updated Jun 20, 2026 · Updated 40 times
Summary
This phase 2 trial tests giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant in 72 patients with leukemia or myelodysplastic syndrome in remission. The goal is to prevent the cancer from coming back after the transplant while causing fewer side effects than standard treatments. Participants also receive drugs to prevent rejection and are followed for at least 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
clofarabine and melphalan chemotherapy
What this could lead to
If successful, this approach could reduce the chance of leukemia returning after a stem cell transplant, with fewer side effects than standard treatments.
What could go wrong
This is a phase 2 trial with only 72 participants, so results may not apply to everyone. The chemotherapy itself can cause serious side effects, and the transplant carries risks like graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.